Diclofenac-clotrimazole for treating recurrent vulvovaginal candidiasis

Diclofenac-clotrimazole is in clinical development for the treatment of recurrent vulvovaginal candidiasis (RVVC). Vulvovaginal candidiasis (genital thrush) is an inflammation of the vagina and/or vulva caused by a superficial fungal infection (usually yeast). Symptoms of RVVC include vulval or vaginal itch and irritation, a non-offensive vaginal discharge, painful intercourse, and painful urination. Recurrent RVVC refers to four or more episodes within a year. Affected patients frequently suffer from long-lasting pain and impairment, such as avoidance of sexual activity and depression, which results in significantly impaired quality of life. RVVC is chronic and difficult to treat with limited therapeutic options available, thereby highlighting the need for new therapies for this indication.